Form 4: Lexeo Therapeutics Director Steven Altschuler Receives Equity Grant

Steven Altschuler, a Director at Lexeo Therapeutics, Inc., was granted 25,000 stock options with an exercise price of $4.18 per share, vesting on the earlier of June 26, 2026, or the next annual stockholders meeting.

Summary

• Steven Altschuler, a Director of Lexeo Therapeutics, Inc. (LXEO), was granted 25,000 stock options.
• The options have an exercise price of $4.18 per share.
• The options were granted on June 26, 2025.
• 100% of the shares underlying the option will vest and become exercisable on the earlier of June 26, 2026, or the date of Lexeo Therapeutics' next annual stockholders meeting.
• Vesting is subject to Steven Altschuler's continuous service to the company.
• The options expire on June 25, 2035.
• Following this transaction, Steven Altschuler beneficially owns 25,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options is a positive signal as it aligns the director's interests with shareholder value creation, although it does not represent an immediate financial gain for the company.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value creation of Lexeo Therapeutics.
• Equity compensation is a standard method to incentivize and retain key personnel.

Negatives

• The options are not immediately exercisable and require future vesting, subject to continuous service.
• The value of the options is dependent on the future stock price exceeding the exercise price of $4.18.

Future Outlook

The equity grant incentivizes the director to contribute to the company's long-term growth and share price appreciation, as the value of the options is tied to future stock performance.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, aligning executive and board member incentives with shareholder interests and long-term company performance.

Related Party Transactions

• The grant of 25,000 stock options to Steven Altschuler, a Director, constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: Interests are aligned with the director through equity compensation, potentially leading to better long-term performance.

Next Steps

• Continued service by the director to meet vesting conditions.
• Potential exercise of options by the director after vesting, subject to market conditions.

Key Dates

Recommendation

Keywords

Lexeo Therapeutics, LXEO, Steven Altschuler, Stock Options, Director, SEC Form 4, Insider Transaction, Equity Grant, Compensation